Company Filing History:
Years Active: 1999-2001
Title: Innovations in Angiogenesis Inhibition by Taturo Udagawa
Introduction
Taturo Udagawa is a notable inventor based in Jamaica Plain, MA (US). He has made significant contributions to the field of medical research, particularly in the area of angiogenesis inhibition. With a total of 2 patents, Udagawa's work focuses on innovative methods to combat diseases associated with abnormal blood vessel growth.
Latest Patents
Udagawa's latest patents include groundbreaking inventions aimed at inhibiting angiogenesis. The first patent, titled "Methods for the inhibition of angiogenesis with arglabin," relates to the treatment of diseases mediated by angiogenesis, particularly cancer. This invention emphasizes the use of cytochalasin derivatives to inhibit neovascularization and treat angiogenesis-associated diseases. The second patent, "Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis," further explores the use of new isoindolinone compounds and their compositions for the same purpose. Both patents highlight Udagawa's commitment to advancing medical treatments through innovative research.
Career Highlights
Taturo Udagawa is affiliated with the Children's Medical Center Corporation, where he continues to contribute to the field of medical research. His work has garnered attention for its potential impact on cancer treatment and other diseases linked to angiogenesis.
Collaborations
Udagawa has collaborated with esteemed colleagues, including Robert J D'Amato and Jamshed H Shah. These partnerships have enhanced the scope and depth of his research, leading to significant advancements in the understanding of angiogenesis.
Conclusion
Taturo Udagawa's innovative work in the field of angiogenesis inhibition showcases his dedication to improving medical treatments. His patents reflect a strong commitment to addressing critical health challenges through scientific research and collaboration.